Mazzariello Gina
Known title: Chief Legal OfficerCIK: 0001913765
Associated companies
Transaction History
| AMLX | ▼ Sell | Open Market | 9,525 | $309K | 9/10/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 11 | $367 | 9/10/2026 | View on chart |
| AMLX | ▲ Buy | Grant | 21,284 | $0 | 8/18/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 15,000 | $264K | 7/10/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 15,000 | $275K | 7/9/2026 | View on chart |
| AMLX | ▲ Buy | Grant | 74,660 | $0 | 3/5/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 6,844 | $99K | 3/2/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 3,419 | $48K | 2/23/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 3,448 | $51K | 2/2/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 8,828 | $129K | 9/30/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 15,000 | $125K | 8/13/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 15,000 | $121K | 8/12/2025 | View on chart |
| AMLX | ▼ Sell | Gift | 1,000 | $0 | 5/22/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 9,192 | $32K | 3/31/2025 | View on chart |
| AMLX | ▲ Buy | Grant | 63,851 | $0 | 3/6/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,611 | $5K | 3/3/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 4,169 | $13K | 2/24/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 3,678 | $13K | 2/3/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 8,709 | $28K | 9/30/2024 | View on chart |
| AMLX | ▼ Sell | Open Market | 10,455 | $20K | 5/15/2024 | View on chart |
| AMLX | ▲ Buy | Grant | 80,560 | $0 | 4/16/2024 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,540 | $29K | 3/5/2024 | View on chart |
| AMLX | ▲ Buy | Grant | 36,667 | $0 | 2/26/2024 | View on chart |
| AMLX | ▼ Sell | Open Market | 2,838 | $53K | 2/23/2024 | View on chart |
| AMLX | ▼ Sell | Open Market | 6,164 | $129K | 8/15/2023 | View on chart |
| AMLX | ▼ Sell | Gift | 500 | $0 | 5/17/2023 | View on chart |
| AMLX | ▲ Buy | Grant | 18,333 | $0 | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 3,586 | $124K | 2/24/2023 | View on chart |
| AMLX | ▲ Buy | Grant | 41,000 | $0 | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.